Management of Pemphigus in COVID-19 Pandemic Era; a Review Article

Fahimeh Abdollahimajd¹, Mohammad Shahidi-Dadras¹, Reza M Robati¹²∗, Sahar Dadkhahfar¹†

¹. Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
². Department of Dermatology, Loghman Hakim Hospital, Shahid Beheshti of Medical Sciences, Tehran, Iran.

Received: April 2020; Accepted: April 2020; Published online: 18 April 2020

Abstract: The novel coronavirus is rapidly spreading around the world. Since the public announcement of the COVID-19 outbreak, several concerns have been raised by dermatologists as well as pemphigus patients who take immunosuppressive drugs. In this paper, we review the literature about the common treatment of pemphigus with a focus on the lessons from similar epidemics to find a proper suggestion to manage pemphigus in the COVID-19 pandemic era. The effect of many of the drugs used for treatment of Pemphigus vulgaris (PV) on COVID-19 is not clear. We also do not have data on the impact of this autoimmune disease, which may involve the mucous membranes, on the acquisition or course of COVID-19. We are currently in the midst of a pandemic and evaluating the effect of COVID-19 on the population of susceptible patients suffering from auto-immune diseases like pemphigus is essential. The evidence on best ways to manage patients with underlying conditions, such as pemphigus, during the outbreak of COVID-19 is evolving and the data is updated every day.

Keywords: COVID-19; pemphigus; severe acute respiratory syndrome coronavirus 2; therapy

Cite this article as: Abdollahimajd F, Shahidi-Dadras M, M Robati R, Dadkhahfar S. Management of Pemphigus in COVID-19 Pandemic Era; a Review Article. Arch Acad Emerg Mede. 2020; 8(1): e51.

1. Introduction

The 2019 novel coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) is spreading around the world and has caused a pneumonia outbreak originating in Wuhan, China. The disease was later named coronavirus disease 2019 (COVID-19) in February 2020, by WHO (1). The epidemiological and clinical characteristics of patients, as well as risk factors for mortality and clinical course of illness have been illustrated (2). According to the current evidence, SARS-Cov-2 commonly involves individuals aged 30-80 years and has low mortality in healthy individuals but can be life-threatening, resulting in severe illness and even death due to sepsis, acute respiratory distress syndrome (ARDS) and multi-organ failure (2). Pemphigus vulgaris is a potentially life-threatening autoimmune bullous disease affecting the skin and mucosa and is caused by autoantibodies directed against desmoglein 1 and desmoglein 3 adhesion molecules of the epidermis (3, 4). Severe cases of PV represent a true medical emergency (5). Since the public announcement of the COVID-19 outbreak, several concerns have been raised by dermatologists as well as pemphigus patients who take immunosuppressive drugs. These concerns include the need for proper disease control with minimal immune suppression to avoid possible fatal outcomes. It is also crucial to understand how the underlying mechanisms in COVID-19 (e.g. cytokine release storm leading to interstitial pulmonary inflammation, extensive lung damage and acute respiratory distress syndrome) (6) could affect those auto-immune diseases such as pemphigus.

In this paper, we review the literature on the common treatments of pemphigus with a focus on lessons from similar epidemics to find a proper suggestion to manage pemphigus in the COVID-19 pandemic era.

2. Systemic corticosteroids

Historically, systemic corticosteroids, usually oral prednisone alone or in combination with immunsuppressive drugs, have been used as the mainstay treatment in pemphi-
rituximab (RTX) is a chimeric monoclonal anti-CD20 antibody that causes depletion of CD20-expressing B cells (17, 18). Early treatment with rituximab has resulted in higher remission rates, long-term clinical response, lower incidence of serious adverse events and rapid prednisone tapering compared to old immunosuppressive therapies making its approval as a first-line therapy in pemphigus possible (19). Rituximab is generally considered safe in patients with pemphigus vulgaris and serious infections, while reported, are rare. Although single RTX infusions do not seem to impair memory responses against known pathogens (20), patients may exert a defective immune reaction against new pathogens and life-threatening infections, including sepsis, have been reported following RTX treatment (21). Opportunistic infections such as cytomegalovirus infection and Pneumocystis pneumonia (PCP), although extremely rare and limited to sporadic case reports, have been reported (22, 23). The risk of reactivation of hepatitis B and C viruses as well as tuberculosis has also been reported (17).

It should be noted that protective humoral immunity in the central nervous system (CNS) requires peripheral CD19-dependent germinal center formation following neurotrophic coronavirus infection (24) and there are evidence that show SARS-CoV-2 targets CNS (25). Although the expression of ACE 2 (the host cell-surface receptor for SARS-CoV-2 envelope spike glycoprotein) in the brain has been proposed, the exact mechanism of CNS involvement in COVID-19 is not known, yet (25). Accordingly, since the characteristic of the immune response against SARS-CoV-2 has not been identified, the potential risks of treating pemphigus with rituximab should be taken into account. Special attention must be paid to close monitoring of the patients and tapering concurrent corticosteroids to minimize susceptibility to life-threatening infections. This risk should be weighed against the prominent and effective role of RTX in treatment of pemphigus and reducing the number of follow up visits (19).

4. Other immunosuppressive agents

Most guidelines suggest azathioprine (AZA) or mycophenolate mofetil (MMF) as first-line steroid-sparing agents for treatment of pemphigus rather than other adjuvant immunosuppressants (18). Nevertheless, different variables such as age and comorbidities of the patients, dermatologist’s personal experience and costs need to be considered since other drugs, such as cyclophosphamide, also show efficacy (8). It should be noted that in comparison to corticosteroid alone, these drugs mainly exert a corticosteroid-sparing effect that leads to a reduction in the risk of relapse by 29% rather than achieving remission (26). Currently, data regarding the administration of these drugs during COVID-19 are scarce and inconclusive. We recommend that these drugs only be discontinued in proven cases of COVID-19. It is noteworthy that there are reports of atypical presentation of Middle East respiratory syndrome virus (MERS-CoV) in patients who received immunosuppressive drugs; therefore, careful monitoring of patients for atypical symptoms should be taken into account (27).

The administration of intravenous immunoglobulin (IVIg) is a therapeutic option in patients with severe/refractory PV (28). Since IVIg might be the safest immunomodulator for long-term use in all age groups (29), treatment with IVIg has been proposed as a potential option for COVID-19 (6) but data are scarce and controversial. In pemphigus patients with COVID-19 and flare of PV, this therapeutic option can be considered but should be weighed against possible side effects such as thromboembolism in severely ill patients (30).
5. Recommendations

Patients with pemphigus need proper treatment for their underlying condition; however, during the outbreak of COVID-19, these patients may carry the risk of severe infections with disastrous outcomes. Figure 1 is a proposed algorithm for management of patients with pemphigus during the COVID-19 outbreak based on the former consensus on treatment of pemphigus and the current evidence on COVID-19. The following issues should be particularly considered.

• Clear information should be given to patients and caregivers to avoid panic and mismanagement.
• Application of teledermatology resources for close follow up and monitoring of the patients to minimize patient’s referral to healthcare centers could be very helpful (31).
• Patients should be followed at regular intervals with a focus on screening the patients for symptoms of COVID-19.
• Healthcare professionals who are in close contact with these patients should be monitored and be vigilant in using recommended precautions and proper ethical teledermatology practice (31).

• Psychological tolerance of patients during quarantine, especially in those who receive high doses of corticosteroids leading to mood swings, should be monitored and possible coping strategies should be discussed.
• The possible flare of the underlying condition should be seriously considered in cases of drug discontinuation without reasonable indication.
• Patients with milder disease can be treated less aggressively with local steroids (topical or intraleSIONal), dapsone and doxycycline (7).
• If indicated, it is better to administer RTX in an infusion center outside the hospitals that are treating COVID-19 patients.
• With regard to the current and emerging treatments of COVID-19 such as anti-malaria drugs (32) and IL6 inhibitors (33), dermatologists have to consider possible drug interactions or more rigorous prophylactic strategies in PV patients, respectively.
6. Conclusion

We are currently in the midst of a pandemic and evaluating the effect of COVID-19 on the population of susceptible patients suffering from auto-immune diseases like pemphigus is essential. Many patients with PV may present to emergency rooms needing emergent care. The effect of many of the drugs used for treatment of Pemphigus vulgaris (PV) on COVID-19 is not clear. We also do not have data on the impact of this autoimmune disease, which may involve the mucous membranes, on the acquisition or course of COVID-19. Despite these limitations, the evidence on best ways to manage patients with underlying conditions, such as pemphigus, during the outbreak of COVID-19 is evolving and the data is updated every day. We hope the issues brought up by this paper can help physicians to make the best decisions for their patients.

7. Declarations

7.1. Acknowledgements
None.

7.2. Authors Contributions
FA, M.S, R.M.R, and S.D contributed to the idea, design and implementation of this review article, and to the writing of the manuscript. All the authors approved the final submitted version of this manuscript.

Authors ORCIDs
Fahimeh Abdollahimajd: 0000-0002-9463-0665
Mohammad Shahidi-Dadras: 0000-0001-7789-1997
Reza M Robati: 0000-0002-7947-8642
Sahar Dadkhahfar: 0000-0003-4058-2562

7.3. Funding Support
None.

7.4. Conflict of Interest
None.

References

1. Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020;25(3):278-80.
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; pii: S0140-6736(20)30566-3.
3. Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med. 2006;355(17):1800-10.
4. Wu H, Wang ZH, Yan A, Lyle S, Fakharzadeh S, Wahl JK, et al. Protection against pemphigus foliaceus by desmoglein 3 in neonates. N Eng J Med. 2006;343(1):31-5.
5. Kridin K, Zelber-Sag S, Bergman R. Pemphigus vulgaris and pemphigus foliaceus: differences in epidemiology and mortality. Act Derm Venereol. 2017;97(8-9):1095-9.
6. Wang LS, Wang YR, Ye DW, Liu QQ. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2020:105948.
7. Zhao CY, Murrell DF. Pemphigus vulgaris: an evidence-based treatment update. Drugs. 2015;75(3):271-84.
8. Gheisari M, Faraji Z, Dadras MS, Nasiri S, Robati RM, Moravej H, et al. Methyldprednisolone pulse therapy plus adjuvant therapy for pemphigus vulgaris: an analysis of 10 years' experience on 312 patients. Dermatol Ther. 2019;32(5):e13057.
9. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9(8):493-504.
10. Shahidi-Dadras M, Pishgahi M, Tabary M, Kheradmard Z, Araghi F, Dadkhahfar S, et al. Cardiac function in pemphigus vulgaris patients before and after steroid pulse therapy. J Dermatolog Treat. 2020;1-5.
11. Pishgahi M, Dadkhahfar S, Robati RM, Kheradmard Z, Shahidi-Dadras M, Zargari O, et al. Electrocardiographic changes after high-dose corticosteroid pulse therapy in pemphigus patients. J Dermatolog Treat. 2018;29(8):802-5.
12. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473-5.
13. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343.
14. Guo L, Han Y, Li J, Chen Q, Ren Y, Wu Q, et al. Long-term outcomes in patients with severe acute respiratory syndrome treated with oseltamivir: a 12-year longitudinal study. Int J Clin Exp Med. 2019;12(10):12464-71.
15. Ni Y-N, Chen G, Sun J, Liang B-M, Liang Z-A. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Critical Care. 2019;23(1):99.
16. Sinha P, Chatterjee M, Vasudevan B. Pemphigus vulgaris: A dermatological sequel of severe H1N1 infection. Indian Dermatol Online J. 2014;5(2):216-7.
17. Didona D, Maglie R, Eming R, Hertl M. Pemphigus: Current and Future Therapeutic Strategies. Front Immunol. 2019;10:1418.
18. Murrell DF, Pena S, Joly P, Marinovic B, Hashimoto T, Diaz LA, et al. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. J Am Acad Dermatol. 2020;82(3):575-85 e1.
19. Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031-40.

20. Cho A, Bradley B, Kauffman R, Priyamvada L, Kovalenkov Y, Feldman R, et al. Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab. JCI insight. 2017;2(12). pii: 93222.

21. Kasperkiewicz M, Eming R, Behzad M, Hunzelmann N, Meurer M, Schulze-Koops H, et al. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges. 2012;10(10):727-33.

22. Chiu H-Y, Chang C-Y, Hsiao C-H, Wang L-F. Concurrent cytomegalovirus and herpes simplex virus infection in pemphigus vulgaris treated with rituximab and prednisolone. Acta Derm Venereol. 2013;93(2):200-1.

23. Wei K, Wang Y, Wang W, Chen W. Fatal infection of Pneumocystis jiroveci pneumonia in a pemphigus patient treated with rituximab. J Eur Acad Dermatol Venereol. 2017;31(8):e350-e351.

24. Atkinson JR, Bergmann CC. Protective humoral immunity in the central nervous system requires peripherally CD19-dependent germinal center formation following coronavirus encephalomyelitis. J Virol. 2017;91(23):e01352-17.

25. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neutrotropic Mechanisms. ACS Chem Neurosci. 2020;11(7):995-998.

26. Atzmony L, Hodak E, Leshem YA, Rosenbaum O, Gdalevich M, Anhalt GJ, et al. The role of adjuvant therapy in pemphigus: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):264-71.

27. Kim S-H, Ko J-H, Park GE, Cho SY, Ha YE, Kang JM, et al. Atypical presentations of MERS-CoV infection in immunocompromised hosts. J Infect Chem. 2017;23(11):769-73.

28. Brown AE, Motaparthi K, Hsu S. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients. Dermatol Online J. 2018;23(12).

29. Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020;92(5):479-90.

30. Lew TW, Kwek T-K, Tai D, Earnest A, Loo S, Singh K, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA. 2003;290(3):374-80.

31. Pathoulas JT, Stoff BK, Lee KC, Farah RS. Ethical Outpatient Dermatology Care During the Coronavirus (COVID-19) Pandemic. J Am Acad Dermatol. 2020 May;82(5):1272-1273.

32. Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 Mar 12:105938.

33. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; pii: S0140-6736(20)30628-0.